CO6270213A2 - Composiciones farmaceuticas que comprenden acido montelukast y un unhibidor depde-4 o un corticoesteroide inhalado para administracion por inhalacion - Google Patents

Composiciones farmaceuticas que comprenden acido montelukast y un unhibidor depde-4 o un corticoesteroide inhalado para administracion por inhalacion

Info

Publication number
CO6270213A2
CO6270213A2 CO10047531A CO10047531A CO6270213A2 CO 6270213 A2 CO6270213 A2 CO 6270213A2 CO 10047531 A CO10047531 A CO 10047531A CO 10047531 A CO10047531 A CO 10047531A CO 6270213 A2 CO6270213 A2 CO 6270213A2
Authority
CO
Colombia
Prior art keywords
preparation
inhaled
unhibitor
depde
corticoesteroid
Prior art date
Application number
CO10047531A
Other languages
English (en)
Inventor
Roch Thibert
Original Assignee
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Ltd filed Critical Merck Frosst Canada Ltd
Publication of CO6270213A2 publication Critical patent/CO6270213A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

1.- Una preparacion medicinal que comprende acido montelukast y un segundo agente activo seleccionado de un inhibidor de PDE-4 y un corticoesteroide inhalado como una preparacion combinada para la administracion por inhalacion. 2.- Una preparacion de la Reivindicacion 1 en la que dicho segundo agente activo es un Compuesto X que tiene la formula:3.- Una preparacion de la Reivindicacion 1 en la que dicho segundo agente activo es mometasona furoato. 4.- Una preparacion de la Reivindicacion 1 adaptada para usar en un inhalador de polvo seco o un inhalador de dosis medida.5.- Una preparacion de la Reivindicacion 2 adaptada para usar en un inhalador de polvo seco o en un inhalador de dosis medida. 6.- Una preparacion de la Reivindicacion 3 adaptada para usar en un inhalador de polvo seco o en un inhalador de dosis medida. 7.- Un inhalador de polvo seco que contiene la preparacion medicinal de la Reivindicacion 1. 8.- Un inhalador de dosis medida que contiene la preparacion medicinal de la Reivindicacion 1.
CO10047531A 2007-10-25 2010-04-22 Composiciones farmaceuticas que comprenden acido montelukast y un unhibidor depde-4 o un corticoesteroide inhalado para administracion por inhalacion CO6270213A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32707P 2007-10-25 2007-10-25

Publications (1)

Publication Number Publication Date
CO6270213A2 true CO6270213A2 (es) 2011-04-20

Family

ID=40579006

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10047531A CO6270213A2 (es) 2007-10-25 2010-04-22 Composiciones farmaceuticas que comprenden acido montelukast y un unhibidor depde-4 o un corticoesteroide inhalado para administracion por inhalacion

Country Status (19)

Country Link
US (1) US20100210611A1 (es)
EP (1) EP2211863A4 (es)
JP (1) JP2011500731A (es)
KR (1) KR20100072295A (es)
CN (1) CN101909626A (es)
AU (1) AU2008316283A1 (es)
CA (1) CA2701956A1 (es)
CO (1) CO6270213A2 (es)
CR (1) CR11439A (es)
DO (1) DOP2010000122A (es)
GT (1) GT201000107A (es)
IL (1) IL205182A0 (es)
MA (1) MA33705B1 (es)
MX (1) MX2010004529A (es)
NI (1) NI201000069A (es)
NZ (1) NZ584876A (es)
RU (1) RU2470639C2 (es)
WO (1) WO2009052624A1 (es)
ZA (1) ZA201002562B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012168907A1 (en) 2011-06-10 2012-12-13 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising revamilast and montelukast or zafirlukast
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
WO2015110394A1 (en) 2014-01-22 2015-07-30 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma with a pde4 inhibitor (and in combination with a leukotriene modifier)
CN108267531B (zh) * 2016-12-31 2022-01-11 天津金耀集团有限公司 一种环索奈德有关物质hplc测定方法
IT201900014178A1 (it) * 2019-08-06 2021-02-06 Genetic S P A Esteri del montelukast e loro formulazioni farmaceutiche

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
US20040214805A1 (en) * 1999-11-02 2004-10-28 Smithkline Beecham Corporation Method and compositions for treating pulmonary diseases
AU2002227123A1 (en) * 2000-11-07 2002-05-21 Merck And Co., Inc. Method of treatment with a combination of a pde4 inhibitor and a leukotriene antagonist
JO2311B1 (en) * 2001-08-29 2005-09-12 ميرك فروست كندا ليمتد Alkyl inhibitors Ariel phosphodiesterase-4
US20050014762A1 (en) * 2001-09-19 2005-01-20 Rolf Beume Combination
DE10237739A1 (de) * 2002-08-17 2004-02-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative Arzneimittel enthaltend ein neues Anticholinergikum in Kombination mit Corticosteroiden und Betamimetika
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
PL1670482T5 (pl) * 2003-09-16 2022-10-03 Covis Pharma Gmbh Zastosowanie cyklezonidu w leczeniu chorób układu oddechowego
EP1678139B1 (en) * 2003-10-10 2011-08-31 Synhton B.V. Solid-state montelukast
JP4700014B2 (ja) * 2004-02-06 2011-06-15 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト 呼吸器系疾患の治療用の抗コリン作用薬及び４型ホスホジエステラーゼの組合せ剤
EP1616567A1 (en) * 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts
CA2601179A1 (en) * 2005-03-16 2006-09-21 Elan Pharma International Limited Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations
CA2595791C (en) * 2005-03-16 2013-10-08 Meda Pharma Gmbh & Co. Kg The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases
JP2009509980A (ja) * 2005-09-28 2009-03-12 メルク フロスト カナダ リミテツド 篩分けされたラクトースを含むエアゾール粉末製剤

Also Published As

Publication number Publication date
NZ584876A (en) 2012-06-29
RU2470639C2 (ru) 2012-12-27
MA33705B1 (fr) 2012-11-01
CN101909626A (zh) 2010-12-08
AU2008316283A1 (en) 2009-04-30
US20100210611A1 (en) 2010-08-19
CR11439A (es) 2010-06-21
JP2011500731A (ja) 2011-01-06
KR20100072295A (ko) 2010-06-30
RU2010120806A (ru) 2011-11-27
GT201000107A (es) 2012-03-13
EP2211863A1 (en) 2010-08-04
NI201000069A (es) 2010-08-23
WO2009052624A9 (en) 2010-11-25
DOP2010000122A (es) 2010-07-15
EP2211863A4 (en) 2012-07-25
CA2701956A1 (en) 2009-04-30
ZA201002562B (en) 2011-06-29
WO2009052624A1 (en) 2009-04-30
MX2010004529A (es) 2010-05-10
IL205182A0 (en) 2010-11-30

Similar Documents

Publication Publication Date Title
ECSP088653A (es) Formulacion farmacéutica para aerosoles con dos o más principios activos y al menos una sustancia tensoactiva
JP2007106777A5 (es)
NZ585856A (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
PE20141036A1 (es) Nueva dosificacion y formulacion
AR079726A1 (es) Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc) . composicion farmaceutica.frasco de aerosol. metodo.conjunto de componentes
RU2008124825A (ru) Органические соединения, включающие соль гликопиррония
BR112015027017A2 (pt) composições farmacêuticas inaláveis e dispositivos inaladores que contêm as mesmas
CO6270213A2 (es) Composiciones farmaceuticas que comprenden acido montelukast y un unhibidor depde-4 o un corticoesteroide inhalado para administracion por inhalacion
ECSP14028814A (es) Nueva forma de dosificación y formulación de abediterol
AR091161A1 (es) Composicion farmaceutica para inhalacion, metodo, uso
CY1117596T1 (el) Φαρμακευτικeς συνθeσεις αερολyματος φορμοτερολης και διπροπιονικης βεκλομεθαζονης
CL2023000998A1 (es) Formulación farmacéutica para inhalador presurizado de dosis medidas
RS54874B1 (sr) Upotreba kompozicije koja obuhvata formoterol i beklometazon dipropionat za tretman egzacerbacije astme
BR112015027247A2 (pt) composições farmacêuticas inaláveis e dispositivos inaladores contendo as mesmas
WO2011093815A3 (en) Pharmaceutical compositions comprising formoterol and mometasone
JP2011500731A5 (es)
CL2012000947A1 (es) Formulación en suspensión para inhalar de dosis medida que comprende fumarato de formoterol dihidratado y propionato de fluticasona y microlin sodico en un propelente hfa; composicion farmaceutica; un producto; uso de 0,01 a 0,1% cromolin sodico, util en asma y rinitis.
WO2011093811A3 (en) Pharmaceutical preparations comprising formoterol and fluticasone
AR094287A1 (es) Metodos y composiciones para administracion de oxibutinina
TR200907914A2 (tr) Kortlkosteroid içeren kuru toz formunda farmasötik bileşim.
WO2011093812A3 (en) Pharmaceutical formulation comprising tiotropium and budesonide in dry powder form
TR200909793A2 (tr) Tiotropyum, mometazon ve bir kromoglisik asit türevi kombinasyonu içeren kuru toz kombinasyonu.
AR098867A1 (es) Composición farmacéutica en polvo seco para inhalación
WO2011093810A3 (en) Dry powder pharmaceutical composition comprising tiotropium and mometasone
AR085443A1 (es) Formulaciones medicinales en aerosol que no dañan la capa de ozono y con bajo efecto invernadero

Legal Events

Date Code Title Description
FC Application refused